A harmonized and collaborative approach to the clinical testing, scale-up and distribution of candidate vaccines to prevent COVID-19 is essential, scientific leaders write in a perspective published today in Science.
As the COVID-19 pandemic continues, government, industry and academia have introduced a variety of vaccine candidates. The authors note that more than one effective vaccine approach likely will be required to successfully protect the global community from SARS-CoV-2, the virus that causes COVID-19. They describe a strategic approach to research and development that would generate essential data for multiple vaccine candidates in parallel.
National Institutes of Health Director Francis S. Collins, M.D., Ph.D., National Institute of Allergy and Infectious Diseases (NIAID) Director Anthony S. Fauci, M.D., Lawrence Corey, M.D., professor in the Vaccine and Infectious Disease Division at the Fred Hutchinson Cancer Research Center in Seattle, and John R. Mascola, M.D., director of NIAID’s Vaccine Research Center are the co-authors of the commentary.
The perspective discusses diverse vaccine candidates and key considerations for development, including the characteristics of various vaccine platforms in terms of prior commercial experience, scalability, and the types of immune responses generated. It also emphasizes that no single vaccine or vaccine platform is likely to meet the global need, highlighting the need for a coordinated strategic approach to vaccine development.
The authors stress that researchers need to learn more about what constitutes a durable protective immune response against COVID-19. They review considerations for vaccine efficacy trials, explaining how trials for several candidate vaccines can be conducted in parallel to generate essential safety and efficacy data and accelerate the licensure and distribution of COVID-19 vaccines. The authors propose specific approaches to harmonizing the clinical testing of multiple vaccine products, including using common clinical trials designs, clinical endpoints, standardized immune assays and a common Data Safety and Monitoring Board.
The authors emphasize that developing COVID-19 vaccines will require unprecedented cooperation from governments, academic institutions, industry, and global philanthropic partners. The ACTIV (Accelerating COVID-19 Therapeutic Interventions and Vaccines) public-private partnership spearheaded by NIH aims to facilitate such collaboration with discussions and collaborations on trial designs and data sharing.
Protecting the entire global community from COVID-19 through vaccination will require significant manufacturing capacity, according to the authors. They emphasize the need to fund the necessary biomanufacturing infrastructure and note possible hurdles in the eventual delivery of vaccines, including cost, distribution systems and cold chain requirements. The authors conclude that strategic collaboration among public and private sectors to effectively accelerate COVID-19 vaccine development is essential.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Covid-19 vaccine
- Imports of Covid-19 vaccines exempted from customs duty till March 31
The government has exempted customs duty on imports of Covid-19 vaccines till March 31, 2023 in a bid to ensure domestic availability amid fears of a surge in coronavirus infections ...
- What is the effectiveness of a multivalent exosome-based COVID-19 vaccine?
Researchers assessed the effectiveness of a multivalent exosome-based coronavirus disease 2019 (COVID-19) vaccine.
- OH Attorney General Yost praises 6th Circuit of Appeals decision blocking Covid-19 vaccine mandate
The court reaffirmed a basic civics lesson: the executive branch cannot demand compliance with a rule it never had the authority to write in the first place.” ...
- Clover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023
China commercial launch in multiple provinces and municipalities expected to begin in Q1 2023, and Clover anticipates a significant and sustained long-term annual booster market for its premium, ...
- A COVID-19 Vaccine Denier Urges Others to Get the Shot
Despite data on the large numbers of people who have suffered and even died from COVID-19, many still don’t fear the virus and remain unvaccinated.
Go deeper with Google Headlines on:
Covid-19 vaccine
[google_news title=”” keyword=”Covid-19 vaccine” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Covid-19
- WHO Recommends That China Monitor Excess COVID-19 Mortality
The World Health Organization (WHO) said on Monday it recommended that China monitor excess mortality from COVID-19 to gain a fuller picture of the impact of the surge in cases there. China said on ...
- As COVID-19 Barrels Through China, Some Are Turning to Black Market Amid Drug Shortages
Hong Kong customs officials seized over the weekend thousands of contraband antivirals headed for the mainland.
- Exercise Helps Blunt the Effects of Covid-19, Study Suggests
Physical activity was linked to better outcomes from Covid-19 even among people who are at higher risk for complications.
- COVID-19 Antigen Detection Reagent Market 2023 Size Segment, Share and Growth Factor Analysis, Future Trends, Top Leaders, Forecast To 2028
Final report will add the analysis of the impact of covid-19 on this industry.” Exclusive demand size analysis of ...
- How COVID-19 Impacting IT Spending in Oil and Gas Market [Up-to-date Report] Size Globally 2023-2026?
Pre and Post Covid Report Is Covered | Final Report Will Add the Analysis of the Impact of Russia-Ukraine War and ...
Go deeper with Google Headlines on:
Covid-19
[google_news title=”” keyword=”Covid-19″ num_posts=”5″ blurb_length=”0″ show_thumb=”left”]